Adopting a strategic approach to managing PV activities for the mature portfolio
One approach many adopt is to work with outsourcing partners to support the regulatory (RA), pharmacovigilance (PV), and quality activities (QA) that are crucial to keeping the product on global markets while reducing the product maintenance costs involved.
Thinking global, acting local with pharmacovigilance expertise
Additionally, companies with products on the market in Europe must follow dedicated European pharmacovigilance regulations, e.g. they must have fully compliant and functional PV systems, overseen by a Qualified Person for Pharmacovigilance (QPPV).2
Rather than having full-time personnel on the ground in multiple global markets, companies often turn to outsourcing partners to support crucial regulatory and safety activities from a central hub, while also ensuring on-the-ground support for local activities.
Adopting a harmonized, forward-looking approach to PV
It also helps companies achieve strategic oversight of all pharmacovigilance responsibilities and paves the way for expanding into new markets without the need to bring on additional staff in those regions.
Another key consideration for companies is the ability to leverage digital innovation tools, such as artificial intelligence, to support key safety activities such as signal management. At the same time, however, investing in digital capabilities is cost-intensive and hard to justify for mature products. Outsourcing management of the mature portfolio, including essential PV activities, to a partner with digital capabilities and expertise gives biopharma companies access to those solutions, as and where it makes business sense.
Reducing complexity with an integrated PV approach
In one example, a German biopharmaceutical organization needed a comprehensive outsourced solution for PV tasks for its large portfolio of marketing authorizations. Key requirements included fully outsourced pharmacovigilance system administration, including a fully validated safety database, support for all operational PV activities, and effective coordination of its worldwide network of strategic partners.
The company turned to Cencora for a PV system that would consolidate its pharmacovigilance responsibilities under a single provider, serving multi-territory needs and providing strategic oversight. The partnership resulted in reduced complexity and streamlined safety activities – from management of the PV system to end-to-end pharmacovigilance oversight to audit and inspection readiness to ongoing intelligence for all drug safety and cross-functional issues.
Adopting an adaptable approach to pharmacovigilance outsourcing
For example, a U.S.-based company may seek a partner to support the QPPV requirements in Europe, leaving that partner to manage PV activities there. Alternatively, if the company has a European office to support central activities (such as the QPPV) but has no local expertise, it might seek a partner to cover local affiliate services rather than having to employ local contact personnel for each market to carry out local literature screening and perform local risk assessments, case intakes, and other local activities. As needs grow and as the portfolio matures, companies may choose to extend the outsourcing engagement to other service lines.
The emphasis is to seek support where it makes greatest strategic sense, such as where the company lacks resources to manage essential activities or where local expertise is required.
As products mature and the company’s focus shifts to new product development, the opportunity to expand the outsourcing relationship to achieve global holistic support across PV, regulatory, and quality can be leveraged – how, when and where it makes strategic business sense.
About the author:
Connect with our team
Sources
1. Big Pharma race to snap up biotech assets as $170 billion patent cliff looms, CNBC, 7 January 2026. Accessed 12 March 2026. https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
2. Pharmacovigilance system: questions and answers, EMA. Accessed 12 March 2026. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/pharmacovigilance-system-questions-answers
Related resources
[ESEMPIO IN EVIDENZA - SI PREGA DI LEGGERE]
SOSTITUISCI QUESTO SPOTLIGHT CON UN ELEMENTO DI CONTENUTO APPROPRIATO!
Modifica il contenuto associato a questo modulo selezionando uno degli elementi di contenuto Immagine completa in evidenza in /Impostazioni sito web/Contenuto condiviso/Banner globali
Cencora.com fornisce traduzioni automatiche per facilitare la lettura del sito web in lingue diverse dall'inglese. Per queste traduzioni, sono stati fatti sforzi ragionevoli per fornire una traduzione accurata, tuttavia, nessuna traduzione automatica è perfetta né è destinata a sostituire i traduttori umani. Queste traduzioni sono fornite come servizio agli utenti di Cencora.com e sono fornite "così come sono". Non viene fornita alcuna garanzia di alcun tipo, espressa o implicita, in merito all'accuratezza, all'affidabilità o alla correttezza di una qualsiasi di queste traduzioni effettuate dall'inglese in qualsiasi altra lingua. Alcuni contenuti (come immagini, video, Flash, ecc.) potrebbero non essere tradotti in modo accurato a causa delle limitazioni del software di traduzione.
Eventuali discrepanze o differenze create nella traduzione di questo contenuto dall'inglese in un'altra lingua non sono vincolanti e non hanno alcun effetto legale per la conformità, l'applicazione o qualsiasi altro scopo. Se vengono identificati errori, ti preghiamo di contattarci. In caso di domande relative all'accuratezza delle informazioni contenute in queste traduzioni, si prega di fare riferimento alla versione inglese della pagina.
